Ipca Laboratories, established in 1949, is a top Indian multinational pharmaceutical company whose headquarters are in Mumbai, Maharashtra. The company deals in pharmaceutical formulations with active pharmaceutical ingredients. There are factories across India and three foreign plants. In addition to operating in its home country, Cape Verde, operations exist in, for example, Guyana, Malta, and Tajikistan. Nevertheless, it maintains a strong presence globally, with operations in over 120 countries, including major markets such as North America, Europe, Asia, and Africa. In this Post You can learn Ipca Laboratories Share Price Target 2024, 2025, 2028, 2030, 2035.
Products include tablets, capsules, injectables, creams, and ointments, as well as oral liquid preparations. Therapeutic areas covered by the range are anti-malarials, anti-hypertensives, and anti-diabetic pain management products for use on non-steroid skin pigmentation disorders, pustuloderma, cancer, and AIDS therapy medications. GMPs were used as a basis for the erection of Ipca Pharmaceutical’s sophisticated production line. Ipca is known for making APIs like Atenolol, Chloroquine Phosphate, Furosemide, and Metoprolol Tartrate. To improve the various formulations and manufacturing processes, Ipca is pushing into new R&D centers focused on cutting-edge applications and development techniques.
The manufacturing facilities of the company in India meet international quality standards and have approvals from organizations such as the US FDA, UK MHRA, and WHO. Financially, Ipca has continued to grow steadily, with its shares trading on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
